510(k) device
Solana Trichomonas Assay
Quidel Corporation · Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY, Class II) · First FDA decision Aug 15, 2016, newest Aug 15, 2016HIV, hepatitis and sexually transmitted infections
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Solana"
MAUDE reports
481
Brand "Solana", since 2015
PubMed studies
45
Mentioning "Solana"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Solana Trichomonas Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Solana Trichomonas Assay510(k)
K161182 · Decided Aug 15, 2016 · 110 days after receipt
Device type: Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38227First Coast Service Options, Inc.Updated Oct 20, 2023
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38229Novitas Solutions, Inc.Updated Oct 20, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Solana", any status and sponsor, newest update first.
Quidel CorporationNot on our public-company list
NCT02566447 · 750 participants · Start Oct 15, 2015 · Primary completion Aug 15, 2016
Device: Solana Trichomonas Assay Testing · For: Trichomonas Vaginalis
Sites: Birmingham, Alabama; Baltimore, Maryland; Chapel Hill, North Carolina · 4 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Solana", and for the whole product code for context.
This brand
481 reports: 481 malfunction, 0 injury, 0 death
Whole product code OUY
30 reports: 25 malfunction, 5 injury, 0 death
Newest reports for this brand
- SOLANA SARS-COV-2 ASSAY (LYO MMX)Malfunction
DIAGNOSTIC HYBRIDS, INC. DBA ORTHO-CLINICAL DIAGNO
0002024674-2024-00682 · Received Oct 29, 2024 · Event dated Oct 1, 2024
Device type: Reagents, 2019-Novel Coronavirus Nucleic Acid (QJR)
Device problem as coded: False Positive Result; No Apparent Adverse Event
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Solana"[tiab]. The summary above synthesizes these.
- Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men.
Gaydos CA, Klausner JD, Pai NP, et al. · Sex Transm Infect · 2017Review
- Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women.
Gaydos CA, Schwebke J, Dombrowski J, et al. · Expert Rev Mol Diagn · 2017Clinical Trial, Research Support, Non-U.S. Gov't
- Cost-Benefit Analysis of Real-Time Influenza Testing for Patients in German Emergency Rooms.
Diel R, Nienhaus A · Int J Environ Res Public Health · 2019Research Support, Non-U.S. Gov't
- Detection of herpes simplex and varicella-zoster virus from skin lesions: comparison of RT-PCR and isothermal amplification for rapid identification.
Jev¡nik M, Lusa L, Ur¡ič T, et al. · Diagn Microbiol Infect Dis · 2020Comparative Study
- Bayesian Evaluation of Solana HSV 1+2/VZV Assay Compared to Viral Culture and Commercial PCR Assay for Cutaneous or Mucocutaneous Specimens.
Arsenault C, Camirand Lemyre F, Martin P, et al. · J Clin Microbiol · 2020Comparative Study, Research Support, Non-U.S. Gov't
- Bibliometric and visualization analysis of global research trends on immunosenescence (1970-2021).
Tan Y, Zhang C, Li D, et al. · Exp Gerontol · 2023Research Support, Non-U.S. Gov't
- Initial Clinical Experience With ClearPoint SmartFrame Array-Aided Stereotactic Procedures.
Sterk B, Taha B, Osswald C, et al. · World Neurosurg · 2022
- Prospective Evaluation of Xpert® Xpress Strep A Automated PCR Assay vs. Solana® Group A Streptococcal Nucleic Acid Amplification Testing vs. Conventional Throat Culture.
Ferrieri P, Thonen-Kerr E, Nelson K, et al. · Curr Microbiol · 2021
- Detection of Herpes Simplex Virus and Varicella-Zoster Virus by Traditional and Multiplex Molecular Methods.
Nikolic D, Kohn D, Yen-Lieberman B, et al. · Am J Clin Pathol · 2019Comparative Study
- Eye tracking in cytotechnology education: "visualizing" students becoming experts.
Mukherjee M, Donnelly A, Rose B, et al. · J Am Soc Cytopathol · 2020Multicenter Study, Research Support, Non-U.S. Gov't
- You're the Flight Surgeon.
Aerosp Med Hum Perform · 2017Case Reports
- Evaluation of Rapid, Molecular-Based Assays for the Detection of Respiratory Syncytial Virus.
Leonardi GP · Intervirology · 2019Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code OUY.
- Xpert TVCepheid · 510(k) 2016
- Aptima Trichomonas Vaginalis Assay - PantherGen-Probe, Inc. · De Novo 2013
- Aptima Trichomonas vaginalis AssayHologic, Inc. · 510(k) 2023
- BD MAX CTGCTV2, BD MAX SystemBecton, Dickinson and Company · 510(k) 2019
- Bd Max Ct/Gc/Tv, Bd Max InstrumentBecton, Dickinson and Company · 510(k) 2016
- AmpliVue Trichomonas AssayQuidel Corporation · 510(k) 2015
- Bd Probetec Trichomonas Vaginalis (Tv) Qx Amplified Dna AssayBecton, Dickinson & CO · 510(k) 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.